Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
- Proceeds to support the clinical development of Atea?s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral diseases
- Investigational new drug application cleared by U.S. Food and Drug Administration to start Phase 2 study of AT-527, Atea?s oral purine nucleotide prodrug for patients hospitalized with moderate COVID-19? ? ???